Literature DB >> 16106063

Applications of major histocompatibility complex class I molecules expressed as single chains.

Tina Primeau1, Nancy B Myers, Y Y Lawrence Yu, Lonnie Lybarger, Xiaoli Wang, Steven M Truscott, Ted H Hansen, Janet M Connolly.   

Abstract

Generation of CD8 T-cell responses to pathogens and tumors requires optimal expression of class I major histocompatibility complex/peptide complexes, which, in turn, is dependent on host cellular processing events and subject to interference by pathogens. To create a stable structure that is more immunogenic and resistant to immune evasion pathways, we have engineered class I molecules as single-chain trimers (SCTs), with flexible linkers connecting peptide, beta2m, and heavy chain. Herein we extend our earlier studies with SCTs to the K(b) ligand derived from vesicular stomatitis virus (VSV) to characterize further SCTs as probes of immune function as well as their potential in immunotherapy. The VSVp-beta2m-K(b) SCTs were remarkably stable at the cell surface, and immunization with DNA encoding SCTs elicited complex-specific antibody. In addition, SCTs were detected by cytotoxic T-lymphocytes specific for the native molecule, and the covalently bound peptide was highly resistant to displacement by exogenous peptide. SCTs can also prime CD8 T-cells in vivo that recognize the native molecule. Furthermore, SCTs were resistant to downregulation by the immune evasion protein mK3 of gamma herpesvirus 68. Moreover, owing to their preassembled nature, SCTs should be resistant to other immune evasion proteins that restrict peptide supply. Thus, SCTs possess therapeutic potential both for prophylactic treatment and for the treatment of ongoing infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16106063     DOI: 10.1385/ir:32:1-3:109

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  36 in total

1.  Optimization of the MHC class I peptide cargo is dependent on tapasin.

Authors:  Anthony P Williams; Chen Au Peh; Anthony W Purcell; James McCluskey; Tim Elliott
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

2.  Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

Authors:  Tim F Greten; Firouzeh Korangy; Gunnar Neumann; Heiner Wedemeyer; Karola Schlote; Astrid Heller; Stephan Scheffer; Drew M Pardoll; Annette I Garbe; Jonathan P Schneck; Michael P Manns
Journal:  J Immunol Methods       Date:  2002-12-20       Impact factor: 2.303

3.  A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.

Authors:  H Hengel; J O Koopmann; T Flohr; W Muranyi; E Goulmy; G J Hämmerling; U H Koszinowski; F Momburg
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

4.  A viral inhibitor of peptide transporters for antigen presentation.

Authors:  K Früh; K Ahn; H Djaballah; P Sempé; P M van Endert; R Tampé; P A Peterson; Y Yang
Journal:  Nature       Date:  1995-06-01       Impact factor: 49.962

5.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

6.  Physical association of the K3 protein of gamma-2 herpesvirus 68 with major histocompatibility complex class I molecules with impaired peptide and beta(2)-microglobulin assembly.

Authors:  Y Y Lawrence Yu; Michael R Harris; Lonnie Lybarger; Lisa A Kimpler; Nancy B Myers; Herbert W Virgin; Ted H Hansen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Gene vaccination with naked plasmid DNA: mechanism of CTL priming.

Authors:  M Corr; D J Lee; D A Carson; H Tighe
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

8.  Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

Authors:  Shiwen Peng; Hongxiu Ji; Cornelia Trimble; Liangmei He; Ya-Chea Tsai; Jessica Yeatermeyer; David A K Boyd; Chien-Fu Hung; T-C Wu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic.

Authors:  E Mottez; P Langlade-Demoyen; H Gournier; F Martinon; J Maryanski; P Kourilsky; J P Abastado
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes.

Authors:  M A Alexander; C A Damico; K M Wieties; T H Hansen; J M Connolly
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

Review 2.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Structural engineering of pMHC reagents for T cell vaccines and diagnostics.

Authors:  Vesselin Mitaksov; Steven M Truscott; Lonnie Lybarger; Janet M Connolly; Ted H Hansen; Daved H Fremont
Journal:  Chem Biol       Date:  2007-08

4.  Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.

Authors:  Sojung Kim; Lijin Li; Curtis P McMurtrey; William H Hildebrand; Jon A Weidanz; William E Gillanders; Michael S Diamond; Ted H Hansen
Journal:  J Immunol       Date:  2010-03-08       Impact factor: 5.422

5.  Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Authors:  Lijin Li; John M Herndon; Steven M Truscott; Ted H Hansen; Timothy P Fleming; Peter Goedegebuure; William E Gillanders
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

6.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

Review 7.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

8.  A single peptide-MHC complex positively selects a diverse and specific CD8 T cell repertoire.

Authors:  Baomei Wang; Tina M Primeau; Nancy Myers; Henry W Rohrs; Michael L Gross; Lonnie Lybarger; Ted H Hansen; Janet M Connolly
Journal:  Science       Date:  2009-11-06       Impact factor: 47.728

9.  Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides.

Authors:  Steven M Truscott; Xiaoli Wang; Lonnie Lybarger; William E Biddison; Cortez McBerry; John M Martinko; Janet M Connolly; Gerald P Linette; Daved H Fremont; Ted H Hansen; Beatriz M Carreno
Journal:  J Biol Chem       Date:  2008-01-14       Impact factor: 5.157

10.  Innovative DNA vaccine to break immune tolerance against tumor self-antigen.

Authors:  Tae Heung Kang; Chih-Ping Mao; Victor La; Alexander Chen; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.